Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184521 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL2184531 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL11671348 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL11671572 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL11752839 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL11447220 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL7540607 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL11671731 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL3815174 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA | |
| SCHEMBL3984265 | 0.98 | LPAR3 (0.59) | LPAR3LPAR2LPAR1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4154277-B1 | METHODS AND SYSTEMS FOR SEPARATION OF THORIUM FROM URANIUM AND THEIR DECAY PRODUCTS | WESTINGHOUSE ELECTRIC CO LLC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4412749-A1 | LU-177 RADIOCHEMISTRY SYSTEM AND METHOD | BWXT Medical Ltd. (CA) | 2024-08-14 | — | — | EP | claimed |
| CN-118265567-A | Lu-177 radiochemistry systems and methods | BWXT医疗有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-117659323-B | Core-shell material based on covalent organic framework and preparation method and application thereof | 四川大学 | 2024-04-02 | — | — | CN | claimed |
| CN-117659323-A | Core-shell material based on covalent organic framework and preparation method and application thereof | 四川大学 | 2024-03-08 | — | — | CN | claimed |
| CN-117504949-A | Method for separating actinium from irradiated thorium target | 国电投核素同创(重庆)科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117051271-A | Separation method of thorium and spallation element | 国电投核素同创(重庆)科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| US-11723992-B2 | Method for extraction and purification of 68GA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | claimed |
| US-11691140-B2 | Method for the preparation of controlled porosity supports for chromatographic separation | UWM RESEARCH FOUNDATION, INC. (US) | 2023-07-04 | — | — | US | claimed |
| WO-2023057816-A1 | LU-177 RADIOCHEMISTRY SYSTEM AND METHOD | BWXT Medical Ltd. (CA) | 2023-04-13 | — | — | WO | claimed |
| US-20170023535-A1 | Multi-Column Separation Apparatus and Method | NATIONAL NUCLEAR LABORATORY LIMITED (GB) | 2017-01-26 | — | — | US | claimed |
| EP-3097413-A1 | MULTI-COLUMN SEPARATION APPARATUS AND METHOD | National Nuclear Laboratory Limited (GB) | 2016-11-30 | — | — | EP | claimed |
| US-20160209387-A1 | METHOD FOR THE QUANTIFICATION OF 227AC IN 223RA COMPOSITIONS | BAYER AS (NO) | 2016-07-21 | — | — | US | claimed |
| EP-3033156-A1 | METHOD FOR THE QUANTIFICATION OF 227AC IN 223RA COMPOSITIONS | Bayer AS (NO) | 2016-06-22 | — | — | EP | claimed |
| WO-2015110806-A1 | MULTI-COLUMN SEPARATION APPARATUS AND METHOD | NATIONAL NUCLEAR LABORATORY LIMITED (GB) | 2015-07-30 | — | — | WO | claimed |
| WO-2015022074-A1 | METHOD FOR THE QUANTIFICATION OF 227AC IN 223RA COMPOSITIONS | ALGETA ASA (NO) | 2015-02-19 | — | — | WO | claimed |
| US-7087206-B2 | Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine | PG RESEARCH FOUNDATION (US) | 2006-08-08 | — | — | US | claimed |
| US-20030194364-A1 | Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine | PG RESEARCH FOUNDATION | 2003-10-16 | — | — | US | claimed |
| US-4483801-A | SULFONATING TRIARYLPHOSPHINE, HUDROLYSIS, AND SOLVENT EXTRACTION | RHONE-POULENC CHIMIE DE BASE (FR) | 1984-11-20 | — | — | US | claimed |
| US-4436654-A | ORGANIC PHOSPHATE OR PHOSPHONATE AND TRICARBOXYLIC ESTER | HITACHI, LTD. (JP) | 1984-03-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723992-B2 | Method for extraction and purification of 68GA | GAA, GBA3, GDA | LPAR3 3790/4885LPAR2 3583/4885LPAR1 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.